Latest Financial Impact News

Page 4 of 70
FortifAI has emerged from its first year as an AI infrastructure company with $20.4 million in cash, but a $29 million statutory loss and sharply lower gaming revenue. The company now needs to turn NOL8’s early testing and partnerships into commercial adoption before its cash-backed growth strategy faces a harder test.
Sophie Babbage
Sophie Babbage
30 Sept 2026
Klevo Group has cut its FY2026 loss by more than three-quarters, turned operating cash flow positive and lifted cash to A$4.32 million. The ASX-listed fintech is now reporting USD 59.2 million of unaudited revenue from its post-year-end stablecoin rollout, although the figure remains difficult to reconcile with the earlier trial disclosure.
Victor Sage
Victor Sage
30 Sept 2026
The Takeovers Panel has extended restrictions preventing Tenstar, Samuel Holdings, Benn Whistler and their associates from dealing in DGR Global shares without prior consent. The orders preserve the existing position while the Panel considers its final response to declared unacceptable circumstances.
Claire Turing
Claire Turing
30 Sept 2026
1414 Degrees reported a wider FY2026 loss, falling cash reserves and a material uncertainty over its ability to continue as a going concern. The company is nevertheless pressing ahead with SiNTL battery commercialisation, a proposed 1 GW data centre precinct and full ownership of Aurora.
Victor Sage
Victor Sage
30 Sept 2026
Atlas Arteria has warned that France may more than double the tax rate applied to eligible toll-road operators, with APRR’s 2025 TEILD bill already reaching €126.7 million. The proposed changes remain subject to parliamentary debate and could be softened before becoming law.
Victor Sage
Victor Sage
30 Sept 2026
Metrics Master Income Trust has been suspended from trading after warning that its audited FY2026 financial report may differ materially from unaudited figures released last month. The final report is expected on 30 September, but the trust has not disclosed the nature or size of the revisions.
Claire Turing
Claire Turing
28 Sept 2026
Boab Metals has signed a binding Heads of Agreement with RE:GROUP for mining services at its Sorby Hills silver-lead project, clearing a key operational milestone ahead of planned production in the second half of 2027. Site establishment is scheduled for January, with mining services targeted to begin by March.
Maxwell Dee
Maxwell Dee
28 Sept 2026
Mesoblast has secured FDA approval to add a new potency assay to commercial release and stability testing for Ryoncil, its approved cell therapy for paediatric graft-versus-host disease. The regulatory decision supports tighter monitoring as manufacturing processes evolve, but the company disclosed no direct financial impact or clinical outcome data.
Ada Torres
Ada Torres
24 Sept 2026
The Takeovers Panel has received a review application from Ida Metal Investments over orders made in the Zenith Minerals takeover matter. The application also seeks interim orders matching those imposed on 6 September, adding another procedural hurdle to the contested bid.
Maxwell Dee
Maxwell Dee
22 Sept 2026
Gold Corporation, trading as The Perth Mint (ASX:GCB), reported a record $100.19 million profit before tax for 2025-26 and recommended its largest-ever dividend to the Western Australian Government. The result was powered by extraordinary precious-metals demand and prices, but the company’s own budget points to a much leaner year ahead.
Victor Sage
Victor Sage
22 Sept 2026
CMS has finalised higher Medicare inpatient reimbursement for EBR Systems’ WiSE System, lifting base payment rates by up to 93% from 1 October 2026. The change improves the commercial payment pathway, although its financial impact will depend on procedure volumes, hospital adoption and NTAP eligibility.
Victor Sage
Victor Sage
21 Sept 2026
Resonance Health has signed a 24-month alliance with London-based Image Analysis Group, making its quantitative MRI endpoints orderable across IAG’s global clinical-trial network. The opportunity is potentially significant, but remains uncontracted: two pilot studies come first, with no minimum revenue or volume commitments.
Victor Sage
Victor Sage
17 Sept 2026

Browse the archive

Full archive